RXEI — RXElite Share Price
Last trade - 00:00- $0.00m
- $7.32m
- $2.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -80.09% | ||
| Return on Equity | -223.91% | ||
| Operating Margin | -606.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 14.17 | 2.81 | n/a | n/a | -80.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RxElite, Inc. (RxElite) develops and markets generic prescription drug products in specialty generic markets. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The Company's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.
Directors
- Peter Williams CHM (74)
- Earl Sullivan CEO (40)
- Rick Schindewolf SVP (50)
- Shannon Stith VFN (32)
- Mark Auerbach DRC (81)
- David Rector DRC (70)
- Last Annual
- December 31st, 2007
- Last Interim
- September 30th, 2008
- Incorporated
- November 16th, 2001
- Public Since
- July 23rd, 2007
- No. of Shareholders
- 300
- No. of Employees
- 47
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 119,705,157
- Address
- 1404 N Main St Ste 200, MERIDIAN, 83642-2828
- Web
- Phone
- +1 2082885550
- Auditors
- HJ & Associates, LLC
Similar to RXEI
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 23:02 UTC, shares in RXElite are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in RXElite last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the RXElite share price has underperformed the S&P500 Index by -16.07% over the past year.
There is no consensus recommendation for this security.
RXElite does not currently pay a dividend.
RXElite does not currently pay a dividend.
RXElite does not currently pay a dividend.
To buy shares in RXElite you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in RXElite had a market capitalisation of $0.00m.
Here are the trading details for RXElite:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RXEI
Based on an overall assessment of its quality, value and momentum RXElite is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RXElite. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in RXElite were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RXElite PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RXElite's management team is headed by:
- Peter Williams - CHM
- Earl Sullivan - CEO
- Rick Schindewolf - SVP
- Shannon Stith - VFN
- Mark Auerbach - DRC
- David Rector - DRC